Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Icon ( (ICLR) ) just unveiled an announcement.
ICON plc announced on June 23, 2025, that it will release its financial results for the second quarter of 2025 after the market closes on July 23, 2025. A conference call and webcast to discuss these results will be held on July 24, 2025. This announcement is significant as it provides stakeholders with insights into the company’s financial performance and strategic direction, potentially impacting its market positioning and investor relations.
The most recent analyst rating on (ICLR) stock is a Buy with a $380.00 price target. To see the full list of analyst forecasts on Icon stock, see the ICLR Stock Forecast page.
Spark’s Take on ICLR Stock
According to Spark, TipRanks’ AI Analyst, ICLR is a Outperform.
Icon’s overall stock score is driven by strong financial performance and a moderately positive technical outlook. The primary concern arises from the earnings call, where operational achievements are offset by revenue challenges and market uncertainties. Valuation remains fair, supporting the stock’s overall stability with potential for growth if revenue issues are addressed.
To see Spark’s full report on ICLR stock, click here.
More about Icon
ICON plc is a leading clinical research organization based in Dublin, Ireland, specializing in healthcare intelligence. The company provides outsourced services to pharmaceutical, biotechnology, medical device, and government and public health organizations. As of March 31, 2025, ICON employed approximately 41,250 employees across 97 locations in 55 countries.
Average Trading Volume: 1,534,001
Technical Sentiment Signal: Sell
Current Market Cap: $11.83B
See more insights into ICLR stock on TipRanks’ Stock Analysis page.